These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 37035178)

  • 1. Lynch syndrome cancer vaccines: A roadmap for the development of precision immunoprevention strategies.
    Sei S; Ahadova A; Keskin DB; Bohaumilitzky L; Gebert J; von Knebel Doeberitz M; Lipkin SM; Kloor M
    Front Oncol; 2023; 13():1147590. PubMed ID: 37035178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model.
    Gebert J; Gelincik O; Oezcan-Wahlbrink M; Marshall JD; Hernandez-Sanchez A; Urban K; Long M; Cortes E; Tosti E; Katzenmaier EM; Song Y; Elsaadi A; Deng N; Vilar E; Fuchs V; Nelius N; Yuan YP; Ahadova A; Sei S; Shoemaker RH; Umar A; Wei L; Liu S; Bork P; Edelmann W; von Knebel Doeberitz M; Lipkin SM; Kloor M
    Gastroenterology; 2021 Oct; 161(4):1288-1302.e13. PubMed ID: 34224739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccines for immunoprevention of DNA mismatch repair deficient cancers.
    Hernandez-Sanchez A; Grossman M; Yeung K; Sei SS; Lipkin S; Kloor M
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35732349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is HLA type a possible cancer risk modifier in Lynch syndrome?
    Ahadova A; Witt J; Haupt S; Gallon R; Hüneburg R; Nattermann J; Ten Broeke S; Bohaumilitzky L; Hernandez-Sanchez A; Santibanez-Koref M; Jackson MS; Ahtiainen M; Pylvänäinen K; Andini K; Grolmusz VK; Möslein G; Dominguez-Valentin M; Møller P; Fürst D; Sijmons R; Borthwick GM; Burn J; Mecklin JP; Heuveline V; von Knebel Doeberitz M; Seppälä T; Kloor M
    Int J Cancer; 2023 May; 152(10):2024-2031. PubMed ID: 36214792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Frameshift Peptide Neoantigen-Based Vaccine for Mismatch Repair-Deficient Cancers: A Phase I/IIa Clinical Trial.
    Kloor M; Reuschenbach M; Pauligk C; Karbach J; Rafiyan MR; Al-Batran SE; Tariverdian M; Jäger E; von Knebel Doeberitz M
    Clin Cancer Res; 2020 Sep; 26(17):4503-4510. PubMed ID: 32540851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lynch Syndrome: From Multidisciplinary Management to Precision Prevention.
    Dal Buono A; Puccini A; Franchellucci G; Airoldi M; Bartolini M; Bianchi P; Santoro A; Repici A; Hassan C
    Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic Landscape of Lynch Syndrome Colorectal Neoplasia Identifies Shared Mutated Neoantigens for Immunoprevention.
    Bolivar AM; Duzagac F; Deng N; Reyes-Uribe L; Chang K; Wu W; Bowen CM; Taggart MW; Thirumurthi S; Lynch PM; You YN; Rodriguez-Pascual J; Lipkin SM; Kopetz S; Scheet P; Lizee GA; Reuben A; Sinha KM; Vilar E
    Gastroenterology; 2024 May; 166(5):787-801.e11. PubMed ID: 38244726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards a vaccine to prevent cancer in Lynch syndrome patients.
    von Knebel Doeberitz M; Kloor M
    Fam Cancer; 2013 Jun; 12(2):307-12. PubMed ID: 23760517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome.
    Chang K; Taggart MW; Reyes-Uribe L; Borras E; Riquelme E; Barnett RM; Leoni G; San Lucas FA; Catanese MT; Mori F; Diodoro MG; You YN; Hawk ET; Roszik J; Scheet P; Kopetz S; Nicosia A; Scarselli E; Lynch PM; McAllister F; Vilar E
    JAMA Oncol; 2018 Aug; 4(8):1085-1092. PubMed ID: 29710228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic Comparison of Lynch Syndrome-associated and "Lynch-like" Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry.
    Mills AM; Sloan EA; Thomas M; Modesitt SC; Stoler MH; Atkins KA; Moskaluk CA
    Am J Surg Pathol; 2016 Feb; 40(2):155-65. PubMed ID: 26523542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current clinical topics of Lynch syndrome.
    Tanakaya K
    Int J Clin Oncol; 2019 Sep; 24(9):1013-1019. PubMed ID: 29744602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies for Lynch syndrome identification in selected and unselected gynecological cancers.
    Carnevali I; Sahnane N; Chiaravalli AM; Di Lauro E; Facco C; Facchi S; Casarin J; Ghezzi F; Sessa F; Tibiletti MG
    Eur J Cancer Prev; 2022 Jul; 31(4):369-376. PubMed ID: 34519692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer risks in Lynch syndrome, Lynch-like syndrome, and familial colorectal cancer type X: a prospective cohort study.
    Bucksch K; Zachariae S; Aretz S; Büttner R; Holinski-Feder E; Holzapfel S; Hüneburg R; Kloor M; von Knebel Doeberitz M; Morak M; Möslein G; Nattermann J; Perne C; Rahner N; Schmiegel W; Schulmann K; Steinke-Lange V; Strassburg CP; Vangala DB; Weitz J; Loeffler M; Engel C;
    BMC Cancer; 2020 May; 20(1):460. PubMed ID: 32448342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetics, diagnosis and treatment of Lynch syndrome: Old lessons and current challenges.
    Duraturo F; Liccardo R; De Rosa M; Izzo P
    Oncol Lett; 2019 Mar; 17(3):3048-3054. PubMed ID: 30867733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum antibodies against frameshift peptides in microsatellite unstable colorectal cancer patients with Lynch syndrome.
    Reuschenbach M; Kloor M; Morak M; Wentzensen N; Germann A; Garbe Y; Tariverdian M; Findeisen P; Neumaier M; Holinski-Feder E; von Knebel Doeberitz M
    Fam Cancer; 2010 Jun; 9(2):173-9. PubMed ID: 19957108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three molecular pathways model colorectal carcinogenesis in Lynch syndrome.
    Ahadova A; Gallon R; Gebert J; Ballhausen A; Endris V; Kirchner M; Stenzinger A; Burn J; von Knebel Doeberitz M; Bläker H; Kloor M
    Int J Cancer; 2018 Jul; 143(1):139-150. PubMed ID: 29424427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opportunities for immunotherapy in microsatellite instable colorectal cancer.
    Westdorp H; Fennemann FL; Weren RD; Bisseling TM; Ligtenberg MJ; Figdor CG; Schreibelt G; Hoogerbrugge N; Wimmers F; de Vries IJ
    Cancer Immunol Immunother; 2016 Oct; 65(10):1249-59. PubMed ID: 27060000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview on population screening for carriers with germline mutations in mismatch repair (MMR) genes in China.
    Zhang M; Chen T
    Hered Cancer Clin Pract; 2021 May; 19(1):26. PubMed ID: 33933134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study.
    Ryan NAJ; McMahon R; Tobi S; Snowsill T; Esquibel S; Wallace AJ; Bunstone S; Bowers N; Mosneag IE; Kitson SJ; O'Flynn H; Ramchander NC; Sivalingam VN; Frayling IM; Bolton J; McVey RJ; Evans DG; Crosbie EJ
    PLoS Med; 2020 Sep; 17(9):e1003263. PubMed ID: 32941469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.
    Geurts-Giele WR; Leenen CH; Dubbink HJ; Meijssen IC; Post E; Sleddens HF; Kuipers EJ; Goverde A; van den Ouweland AM; van Lier MG; Steyerberg EW; van Leerdam ME; Wagner A; Dinjens WN
    J Pathol; 2014 Dec; 234(4):548-59. PubMed ID: 25111426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.